Skip to main content

Advertisement

Fig. 1 | Cancer Cell International

Fig. 1

From: RAC3 influences the chemoresistance of colon cancer cells through autophagy and apoptosis inhibition

Fig. 1

RAC3 acts as a predictive marker for CRC prognosis and chemotherapeutic response: a representative RAC3 Immunohistochemistry in normal colorectal and CRC tissues. b The RAC3 expression levels in normal colorectal tissues and CRC tissues at different pathological stages were determined by qPCR and normalized with GAPDH mRNA. c The RAC3 expression levels are compared between metastatic and primary lesion in patients sensitive or not to FOLFOX treatment (Folic acid-5-fluorouracil and oxaliplatin). The diagram bars show the average ± S.D. of mRNA expression log-transformed values from GSE28702 data bank, platform GPL570 Affymetrix (Santa Clara, CA, USA) *p < 0.01 respect to FOLFOX non-responder in Metastatic lesion. d RAC3 expression levels in three CRC cell lines are compared with normal colorectal and CRC tissues. The diagram bars correspond to average ± S.D. of RAC3 mRNA expression obtained by qPCR and normalized to GAPDH mRNA, *p < 0.001 respect to normal tissue and **p < 0.0001 respect to normal tissue and LoVo cell line. e Western blot was performed to determine the protein levels of RAC3 in the three CRC cell lines. Relative densitometry units (RDU) correspond to the average of densitometry units respect to Tubulin expression, obtained in three independent experiments. f, g Cell viability was determined by crystal violet staining and IC50 doses were calculated with GraphPad software. CRC cells were treated with FUra (0–150 μM) for 72 h (f) or Oxa (0–50 μM) for 24 h (g) p < 0.001 IC50 LoVo respect to HCT 116 to FUra or respect to HCT116 and HT-29 to Oxa

Back to article page